28 March 2024: Clinical Research
Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Predicting Complete Pathological Response in Rectal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy
Mustafa Karaca 1ACDEF* , Ece Salim 2ABDEF , Mustafa Serkan Alemdar 3BDEF , Özge Deniz Karaca 2BEF , Mustafa Özgür Arıcı 3BDEFDOI: 10.12659/MSM.943750
Med Sci Monit 2024; 30:e943750
Table 4 Patient characteristics according to pathological response.
| Variables | Complete response (n=34) | Near-complete response (n=61) | Partial response (n=68) | No response (n=24) | p |
|---|---|---|---|---|---|
| Age (years)* | 65.38±11.11 | 66.79±10.55 | 62.75±11.8 | 63.08±10.65 | 0.188 |
| Gender** | |||||
| Male | 25 (73.5) | 35 (57.4) | 45 (66.2) | 18 (75) | 0.292 |
| Female | 9 (26.5) | 26 (42.6) | 23 (33.8) | 6 (25) | |
| Comorbid disease** | 10 (29.4) | 26 (42.6) | 27 (39.7) | 12 (50) | 0.430 |
| Diabetes mellitus | 4 (11.8) | 12 (19.7) | 14 (20.6) | 7 (29.2) | 0.434 |
| Hypertension | 0 (0) | 2 (3.3) | 0 (0) | 0 (0) | 0.375 |
| Ulcerative colitis | 6 (17.6) | 12 (19.7) | 11 (16.2) | 5 (20.8) | 0.941 |
| CAD | 0 (0) | 0 (0) | 2 (2.9) | 0 (0) | 0.628 |
| Chemotherapy agent** | |||||
| Capecitabine | 19 (55.9) | 35 (57.4) | 32 (47.1) | 10 (41.7) | 0.463 |
| 5-FU | 15 (44.1) | 26 (42.6) | 36 (52.9) | 14 (58.3) | |
| Type of surgery** | |||||
| LAR | 30 (88.2) | 49 (80.3) | 57 (83.8) | 18 (75) | 0.577 |
| MILES operation | 4 (11.8) | 12 (19.7) | 11 (16.2) | 6 (25) | |
| Hemoglobin at diagnosis* | 13.06±1.81 | 12.47±1.73 | 12.18±2.28 | 12.53±2.5 | 0.247 |
| Neutrophils at diagnosis*** | 5 (3.9–6) | 4.6 (3.8–6) | 5.5 (4.15–6.3) | 5.3 (4.35–6.9) | 0.198 |
| Lymphocytes at diagnosis*** | 1.85 (1.4–2.2) | 1.9 (1.5–2.4) | 1.9 (1.4–2.3) | 1.65 (1.4–2.1) | 0.580 |
| Platelets at diagnosis*** | 275 (206–353) | 287 (239–327) | 287.5 (239.5–337.5) | 261 (235.5–349.5) | 0.903 |
| LDH at diagnosis*** | 190.5 (174–222) | 194 (163–235) | 188 (162.5–220) | 194 (160–230) | 0.756 |
| NLR at diagnosis | 2.93 (1.8–3.67) | 2.43 (2.06–3.13) | 3.06 (2.16–3.98) | 3.29 (2.07–4.07) | 0.127 |
| >3.63 | 9 (26.5) | 9 (14.8) | 22 (32.4) | 10 (41.7) | |
| Results are presented as * mean±SD, ** n (%), *** median (IQR). One-way ANOVA, Kruskal-Wallis test, Pearson chi-square test, Fisher’s Exact test. The same lowercase letters in a row indicate that there is no significant difference between the groups. CAD – coronary artery disease; 5-FU – 5-Fluorouracil; LAR – low anterior resection; LDH – lactate dehydrogenase; NLR – neutrophil/lymphocyte ratio. The same lowercase letters in a row indicate that there is no significant difference between the groups. | |||||